CAS:4394-00-7
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Light yellow to yellow Solid
Array ( [133] => Array ( [id] => 133 [name] => Inhibitors & Antagonists & Agonists [children] => Array ( [352] => Array ( [id] => 352 [name] => Protein Tyrosine Kinase/PTK ) [350] => Array ( [id] => 350 [name] => PI3K/Akt/mTOR ) [351] => Array ( [id] => 351 [name] => Endocrinology & Hormones ) [357] => Array ( [id] => 357 [name] => Angiogenesis ) [358] => Array ( [id] => 358 [name] => HIF ) [363] => Array ( [id] => 363 [name] => Immunology & Inflammation ) [364] => Array ( [id] => 364 [name] => Stem Cells ) [365] => Array ( [id] => 365 [name] => Apoptosis ) [377] => Array ( [id] => 377 [name] => Metabolic Enzyme & Protease ) [379] => Array ( [id] => 379 [name] => Autophagy ) [380] => Array ( [id] => 380 [name] => ER Stress ) [384] => Array ( [id] => 384 [name] => Cell Cycle ) [385] => Array ( [id] => 385 [name] => Cytoskeleton ) [386] => Array ( [id] => 386 [name] => DNA Damage & DNA Repai ) [387] => Array ( [id] => 387 [name] => Epigenetics ) [388] => Array ( [id] => 388 [name] => Ubiquitin ) [389] => Array ( [id] => 389 [name] => JAK/STAT ) [390] => Array ( [id] => 390 [name] => GPCR & G Protein ) [391] => Array ( [id] => 391 [name] => Neuronal Signal Pathway ) [392] => Array ( [id] => 392 [name] => MAPK ) [393] => Array ( [id] => 393 [name] => NF-κB ) [394] => Array ( [id] => 394 [name] => Membrane Transporter & Ion Channel ) [395] => Array ( [id] => 395 [name] => TGF-β/Smad ) [396] => Array ( [id] => 396 [name] => Hippo ) [775] => Array ( [id] => 775 [name] => Antibody-drug Conjugate/ADC Related ) [122] => Array ( [id] => 122 [name] => Others ) ) [num] => 3416 ) )
>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Membrane Transporter & Ion Channel >
Niflumic AcidCAS:4394-00-7
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Light yellow to yellow Solid
CAS | 4394-00-7 |
Chinese Name | 氟尼酸 |
English Name | Niflumic Acid |
Synonyms | Nifluril;Landruma;Forenol |
Molecular Formula | C13H9F3N2O2 |
Molecular Weight | 282.22 |
Solubility | Soluble in DMSO ≥5mg/mL |
Purity | ≥98% |
Appearance | Light yellow to yellow Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
EC | EINECS 224-516-2 |
MDL | MFCD00010569 |
SMILES | C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F |
InChIKey | JZFPYUNJRRFVQU-UHFFFAOYSA-N |
InChI | InChI=1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20) |
PubChem CID | 4488 |
Target Point | Chloride Channel |
Passage | Membrane Transporter&Ion Channel |
Background | It is a calcium - activated chloride channel blocker. |
Biological Activity | Niflumic Acid 是一种钙激活氯通道阻滞剂和 COX-2 抑制剂,其 IC50 值为 100 nM,具有抗癌活性,被用于治疗关节和肌肉疼痛。[1-5] |
IC50 | COX-1: 100nM(IC50)[2] |
In Vitro | Niflumic acid selectively reduces a component of noradrenaline- and 5-HT-induced pressor responses by inhibiting a mechanism which leads to the opening of voltage-gated calcium channels. Niflumic acid(10 and 30 microM)inhibited the noradrenaline and 5-HT induced increase in perfusion pressure.[1] Niflumic acid(NA),a member of the fenamates group of NSAIDs and Cl(-)and Ca(2+)-activated Cl(-)(CAC)channels blocker,induced apoptosis(by ~8 %,24 h treatment)and potentiated(by 8-10 %)apoptotic effect of endoplasmic reticulum Ca(2+)mobilizer thapsigargin(Tg)in human erythroleukemic K562 cell line.[2] Combined niflumic acid(100 和 200 μM;48 h)-ciglitazone treatment synergistically induced apoptotic cell death,activated caspase-9,caspase-3,and induced caspase-3-mediated PARP cleavage. The combination treatment also triggered apoptosis through caspase-8/Bid/Bax activation. Combined niflumic acid-ciglitazone treatment significantly induced ER stress responses.[3] Niflumic acid has proliferation-inhibiting,invasion-suppressing,cell cycle-blocking and apoptosis-promoting effects on CNE-2Z cells through regulation of ERK/MAPK.[4] |
In Vivo | Niflumic acid 30 mg/kg inhibited the secretory response of mucus granules in an asthma model.[5] |
Data Literature Source | [1]. Criddle DN,et al. Inhibitory action of niflumic acid on noradrenaline- and 5-hydroxytryptamine-induced pressor responses in the isolated mesenteric vascular bed of the rat. Br J Pharmacol. 1997 Mar;120(5):813-8. [2]. Kucherenko YV,et al. Niflumic acid affects store-operated Ca(2+)-permeable (SOC) and Ca (2+)-dependent K (+) and Cl (-) ion channels and induces apoptosis in K562 cells. J Membr Biol. 2014 Jul;247(7):627-38. [3]. Kim BM,et al. Combined treatment with the Cox-2 inhibitor niflumic acid and PPARγ ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells. Cancer Lett. 2011 Jan 28;300(2):134-44. [4]. Luo S,et al. Niflumic acid exhibits anti-tumor activity in nasopharyngeal carcinoma cells through affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Int J Clin Exp Pathol. 2015 Sep 1;8(9):9990-10001. [5]. Kondo M,et al. Niflumic acid inhibits goblet cell degranulation in a guinea pig asthma model. Allergol Int. 2012 Mar;61(1):133-42. |
Unit | Bottle |
Specification | 100mg |